Latest Conference Articles

March 29th 2023, 8:02pm

European Lung Cancer Congress

Up-front treatment with osimertinib reduced the risk of brain progression-free survival but provided a comparable overall survival benefit compared with sequential treatment with gefitinib followed by osimertinib in patients with advanced non–small cell lung cancer harboring EGFR mutations.

March 29th 2023, 7:16pm

SGO Annual Meeting

Dimitrios Nasioudis, MD, discusses how the use of next-generation sequencing can help identify the unique molecular profile of endometroid ovarian cancer.

March 29th 2023, 7:11pm

SGO Annual Meeting

Lindsey K. Buckingham, MD, discusses an investigation into the use of patient-reported outcomes from the cancer-specific Geriatric Assessment (GA) to predict frailty in women with ovarian cancer, as well as planning the next steps for this research in other gynecologic cancers.

March 28th 2023, 10:01pm

SGO Annual Meeting

Brian M. Slomovitz, MD, discusses the evaluation of letrozole and ribociclib from the phase 2 GOG 3026 trial in recurrent low-grade serous ovarian carcinoma.

March 28th 2023, 9:58pm

SGO Annual Meeting

Shannon N. Westin, MD, MPH, FACOG, discusses the outcomes of the phase 1b SOLAR trial, which examined olaparib with selumetinib in patients with RAS-mutant gynecologic malignancies and other solid tumors.

March 28th 2023, 9:55pm

SGO Annual Meeting

Pamela T. Soliman, MD, MPH, discusses the use of circulating tumor DNA a clinical trial end point in endometrial cancer.

March 28th 2023, 7:50pm

SGO Annual Meeting

Neoadjuvant treatment with olaparib prior to surgical resection and adjuvant chemotherapy was well tolerated and led to a 100% optimal resection rate in patients with newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer.

March 28th 2023, 7:29pm

SGO Annual Meeting

Meghan K. Berkenstock, MD, discusses the management of antibody-drug conjugate-related ocular toxicities in gynecologic cancers.

March 28th 2023, 6:15pm

SGO Annual Meeting

Ramez N. Eskander, MD, discusses findings from the phase 3 NRG GY018 trial of pembrolizumab plus chemotherapy in patients with endometrial cancer.

March 28th 2023, 6:02pm

SGO Annual Meeting

Dostarlimab plus standard-of-care chemotherapy generated a significant improvement in progression-free survival vs chemotherapy alone for patients with recurrent endometrial cancer, including those with mismatch repair–deficient, microsatellite instability–high tumors.

March 28th 2023, 4:39pm

SGO Annual Meeting

Pembrolizumab plus standard-of-care chemotherapy, followed by maintenance pembrolizumab, reduced the risk of disease progression or death vs chemotherapy alone in patients with mismatch repair–deficient and mismatch repair–proficient advanced or recurrent endometrial cancer.

March 28th 2023, 3:30pm

SGO Annual Meeting

Bruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.

March 28th 2023, 2:15am

SGO Annual Meeting

Mansoor Raza Mirza, MD, discusses findings from the phase 3 RUBY trial in patients with endometrial cancer.

March 27th 2023, 8:57pm

SGO Annual Meeting

Oliver Dorigo, MD, PhD, discusses the clinical efficacy of maveropepimut-S in patients with recurrent ovarian cancer.

March 27th 2023, 8:51pm

SGO Annual Meeting

Rosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.

March 27th 2023, 8:09pm

SGO Annual Meeting

Botensilimab in combination with balstilimab induced durable responses in patients with resistant/refractory ovarian cancer.

March 27th 2023, 7:59pm

SGO Annual Meeting

The combination of lenvatinib plus pembrolizumab produced deep, durable tumor responses in both all-comer and mismatch repair–proficient (pMRR) populations of patients with advanced endometrial cancer, according to data from the phase 3 Study 309/KEYNOTE-775 trial.

March 27th 2023, 6:42pm

SGO Annual Meeting

The combination of toripalimab, bevacizumab, and platinum-based chemotherapy elicited responses in patients with refractory, recurrent or metastatic cervical cancer.

March 27th 2023, 6:41pm

SGO Annual Meeting

Maintenance niraparib did not produce a statistically significant overall survival benefit compared with placebo in patients with recurrent ovarian cancer, according to data from an updated exploratory OS analysis of the phase 3 ENGOT-OV16/NOVA study.

March 27th 2023, 6:34pm

SGO Annual Meeting

Treatment with the oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated in patients with recurrent or persistent uterine serous carcinoma who previously received platinum-based chemotherapy.